Combined blockade of NKG2A and PD-1 or PD-L1 synergizes to reduce tumor growth in a mouse model of B-cell lymphoma by promoting NK and CD8+ T cell cytotoxic activity [78]. Here, KLRC1 is linked to neoplasm.